Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
It will be the first and only global office for traditional medicine in the world
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Subscribe To Our Newsletter & Stay Updated
